| Jeffrey L Wilt, MD | |
|
1000 Oakland Dr, Kalamazoo, MI 49008-1282 | |
| (269) 337-6300 | |
| Not Available |
| Full Name | Jeffrey L Wilt |
|---|---|
| Gender | Male |
| Speciality | Critical Care (intensivists) |
| Experience | 36 Years |
| Location | 1000 Oakland Dr, Kalamazoo, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033226097 | NPI | - | NPPES |
| 0C97618 | Other | MI | BCBS |
| 2904118571 | Other | MI | BCBS OF MICHIGAN |
| 1033226097 | Medicaid | MI | |
| 3161767 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | 4301052876 (Michigan) | Primary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | 4301052876 (Michigan) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Borgess Medical Center | Kalamazoo, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ascension Medical Group Promed | 7315856077 | 233 |
News Archive
Scientists at the Johns Hopkins Kimmel Cancer Center have identified a molecular partnership in pancreatic cancer cells that might help to explain how the disease spreads — metastasizes — in some cases. Their findings reveal urgently needed new targets to treat pancreatic cancer, which strikes nearly 50,000 people in the U.S. each year and has only a 5 percent survival rate five years after diagnosis.
Researchers have identified receptors that cause the pain experienced in cases of irritable bowel syndrome.
A new study by the Substance Abuse and Mental Health Services Administration reveals that only 777 of 13,688 (6 percent) substance abuse treatment facilities surveyed across the nation offer special programs for gay and lesbian clients.
Pembrolizumab, an immunotherapy drug that was extensively evaluated by UCLA cancer researcher Dr. Edward Garon, has been approved by the U.S. Food & Drug Administration as first-line treatment for non-small cell lung cancer (NSCLC).
Immune response measured in tumor biopsies during the course of early treatment predicts which melanoma patients will benefit from specific immune checkpoint blockade drugs, researchers at The University of Texas MD Anderson Cancer Center report in the journal Cancer Discovery.
› Verified 3 days ago
| Entity Name | Ascension Medical Group Promed |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497709869 PECOS PAC ID: 7315856077 Enrollment ID: O20031216000478 |
News Archive
Scientists at the Johns Hopkins Kimmel Cancer Center have identified a molecular partnership in pancreatic cancer cells that might help to explain how the disease spreads — metastasizes — in some cases. Their findings reveal urgently needed new targets to treat pancreatic cancer, which strikes nearly 50,000 people in the U.S. each year and has only a 5 percent survival rate five years after diagnosis.
Researchers have identified receptors that cause the pain experienced in cases of irritable bowel syndrome.
A new study by the Substance Abuse and Mental Health Services Administration reveals that only 777 of 13,688 (6 percent) substance abuse treatment facilities surveyed across the nation offer special programs for gay and lesbian clients.
Pembrolizumab, an immunotherapy drug that was extensively evaluated by UCLA cancer researcher Dr. Edward Garon, has been approved by the U.S. Food & Drug Administration as first-line treatment for non-small cell lung cancer (NSCLC).
Immune response measured in tumor biopsies during the course of early treatment predicts which melanoma patients will benefit from specific immune checkpoint blockade drugs, researchers at The University of Texas MD Anderson Cancer Center report in the journal Cancer Discovery.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeffrey L Wilt, MD 1000 Oakland Dr, Kalamazoo, MI 49008-1282 Ph: () - | Jeffrey L Wilt, MD 1000 Oakland Dr, Kalamazoo, MI 49008-1282 Ph: (269) 337-6300 |
News Archive
Scientists at the Johns Hopkins Kimmel Cancer Center have identified a molecular partnership in pancreatic cancer cells that might help to explain how the disease spreads — metastasizes — in some cases. Their findings reveal urgently needed new targets to treat pancreatic cancer, which strikes nearly 50,000 people in the U.S. each year and has only a 5 percent survival rate five years after diagnosis.
Researchers have identified receptors that cause the pain experienced in cases of irritable bowel syndrome.
A new study by the Substance Abuse and Mental Health Services Administration reveals that only 777 of 13,688 (6 percent) substance abuse treatment facilities surveyed across the nation offer special programs for gay and lesbian clients.
Pembrolizumab, an immunotherapy drug that was extensively evaluated by UCLA cancer researcher Dr. Edward Garon, has been approved by the U.S. Food & Drug Administration as first-line treatment for non-small cell lung cancer (NSCLC).
Immune response measured in tumor biopsies during the course of early treatment predicts which melanoma patients will benefit from specific immune checkpoint blockade drugs, researchers at The University of Texas MD Anderson Cancer Center report in the journal Cancer Discovery.
› Verified 3 days ago
Dr. Eric S Shay, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 601 John St, Suite M-170, Kalamazoo, MI 49007 Phone: 269-381-5060 Fax: 269-381-1655 | |
Michael Trexler, Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1521 Gull Rd, Suite 173, Kalamazoo, MI 49048 Phone: 269-226-5165 | |
Dr. Christopher Rogers, D.O. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 601 John St, Ste 100, Kalamazoo, MI 49007 Phone: 269-373-1222 Fax: 269-373-6270 | |
Desmonda Brady Wixson, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 4613 W Main St Ste A, Kalamazoo, MI 49006 Phone: 269-488-8672 Fax: 269-488-8673 | |
Dr. Kevin L. Beyer, D.O. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1535 Gull Rd, Suite 105, Kalamazoo, MI 49048 Phone: 269-385-9900 Fax: 269-385-2140 | |
Ernest Lee Yoder, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Oakland Dr, Kalamazoo, MI 49008 Phone: 269-337-6300 | |
Valerie Siqueira Duhn, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 521 E. Michigan Ave, Ste 201, Kalamazoo, MI 49007 Phone: 269-349-6759 Fax: 369-349-7450 |